Genevoyager

Genevoyager has launched a state-of-the-art cGMP-compliant CDMO facility equipped with its proprietary One-Bac 4.0 system to enable large-scale production of high-quality AAV vectors. The platform addresses key challenges in AAV manufacturing by improving yields, reducing impurities, eliminating replication competent-AAVs (rcAAV), increasing infectivity/full capsid ratios (>70%), and lowering costs to make gene therapies more accessible globally. The company supports partners from research through commercial scale-up but does not itself sponsor clinical programs or report clinical results as it is primarily a service provider.